Barry Kahan

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. doi request reprint Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment
    Barry Kahan
    The University of Texas Medical School at Houston, Texas Heart Institute, St Luke s Episcopal Hospital, Department of Surgery, Houston 77030, USA
    Expert Opin Drug Saf 10:727-49. 2011
  2. ncbi request reprint Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study
    Barry D Kahan
    Department of Surgery, University of Texas Health Science Center at Houston, Houston, TX, USA
    Transplantation 76:1079-84. 2003
  3. ncbi request reprint Therapeutic drug monitoring of cyclosporine: 20 years of progress
    B D Kahan
    University of Texas Medical School at Houston, Division of Immunology and Organ Transplantation, Houston, TX 77030, USA
    Transplant Proc 36:378S-391S. 2004
  4. ncbi request reprint FTY720: from bench to bedside
    B D Kahan
    University of Texas Medical School at Houston, Division of Immunology and Organ Transplantation, Houston, TX 77030, USA
    Transplant Proc 36:531S-543S. 2004
  5. ncbi request reprint Sirolimus-based immunosuppression: present state of the art
    Barry D Kahan
    Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA
    J Nephrol 17:S32-9. 2004
  6. ncbi request reprint Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection
    Barry D Kahan
    Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA
    Transplantation 78:858-63. 2004
  7. doi request reprint Forty years of publication of transplantation proceedings--the second decade: the cyclosporine revolution
    Barry D Kahan
    Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston Medical School, Houston, Texas 77030, USA
    Transplant Proc 41:1423-37. 2009
  8. ncbi request reprint Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients
    Barry D Kahan
    The University of Texas Medical School at Houston, Division of Immunology and Organ Transplantation, Houston, TX 77030, USA
    Transplantation 80:749-58. 2005
  9. ncbi request reprint Use of sirolimus to facilitate steroid withdrawal from a cyclosporine regimen
    B D Kahan
    Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston, Houston, Texas 77030, USA
    Transplant Proc 38:2842-6. 2006
  10. doi request reprint Fifty years in the vineyard of transplantation: looking back
    B D Kahan
    Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston Medical School, Houston, Texas 77030, USA
    Transplant Proc 43:2853-9. 2011

Detail Information

Publications62

  1. doi request reprint Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment
    Barry Kahan
    The University of Texas Medical School at Houston, Texas Heart Institute, St Luke s Episcopal Hospital, Department of Surgery, Houston 77030, USA
    Expert Opin Drug Saf 10:727-49. 2011
    ..Control of the immune responses is critical for body homeostasis. Immunosuppressive strategies have been critical to this enterprise as they reveal molecular and cellular mechanisms of immune-mediated tissue destruction...
  2. ncbi request reprint Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study
    Barry D Kahan
    Department of Surgery, University of Texas Health Science Center at Houston, Houston, TX, USA
    Transplantation 76:1079-84. 2003
    ..This study examined the safety, pharmacodynamics, and pharmacokinetics of multiple doses of FTY720 in stable renal transplant patients...
  3. ncbi request reprint Therapeutic drug monitoring of cyclosporine: 20 years of progress
    B D Kahan
    University of Texas Medical School at Houston, Division of Immunology and Organ Transplantation, Houston, TX 77030, USA
    Transplant Proc 36:378S-391S. 2004
    ....
  4. ncbi request reprint FTY720: from bench to bedside
    B D Kahan
    University of Texas Medical School at Houston, Division of Immunology and Organ Transplantation, Houston, TX 77030, USA
    Transplant Proc 36:531S-543S. 2004
    ....
  5. ncbi request reprint Sirolimus-based immunosuppression: present state of the art
    Barry D Kahan
    Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA
    J Nephrol 17:S32-9. 2004
    ....
  6. ncbi request reprint Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection
    Barry D Kahan
    Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA
    Transplantation 78:858-63. 2004
    ....
  7. doi request reprint Forty years of publication of transplantation proceedings--the second decade: the cyclosporine revolution
    Barry D Kahan
    Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston Medical School, Houston, Texas 77030, USA
    Transplant Proc 41:1423-37. 2009
    ..Transplantation had now achieved its rightful place in the clinical armamentarium...
  8. ncbi request reprint Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients
    Barry D Kahan
    The University of Texas Medical School at Houston, Division of Immunology and Organ Transplantation, Houston, TX 77030, USA
    Transplantation 80:749-58. 2005
    ..One approach to addressing this problem is identifying agents that display antineoplastic properties concomitant with their immunosuppressive effects...
  9. ncbi request reprint Use of sirolimus to facilitate steroid withdrawal from a cyclosporine regimen
    B D Kahan
    Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston, Houston, Texas 77030, USA
    Transplant Proc 38:2842-6. 2006
    ..Because sirolimus blocks one of the sites affected by steroids, we sought to examine whether substituting this drug mitigated these toxicities...
  10. doi request reprint Fifty years in the vineyard of transplantation: looking back
    B D Kahan
    Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston Medical School, Houston, Texas 77030, USA
    Transplant Proc 43:2853-9. 2011
    ..These experiences have afforded insights into future avenues for preclinical exploration and therapeutic drug development...
  11. doi request reprint The ruby anniversary: forty years of publication of Transplantation Proceedings - the first decade: the flowering of immunology and immunogenetics
    B D Kahan
    University of Texas Medical School at Houston, Department of Surgery, Division of Immunology and Organ Transplantation, Houston, Texas 77030, USA
    Transplant Proc 41:5-10. 2009
    ..Initial clinical successes revealed technical accomplishments that warranted broader application of this technology as described in the second decade of the Proceedings-the advent of cyclosporine...
  12. ncbi request reprint Addition of induction therapy offsets the hazard of marked calcineurin minimization among renal transplant recipients treated with sirolimus
    B D Kahan
    Division of Immunology and Organ Transplantation, The University of Texas Medical School, Houston, TX 77030, USA
    Clin Nephrol 73:344-53. 2010
    ..We sought to examine the improvement in renal function with preserved immunosuppression consequent to reducing de novo cyclosporine (CsA) doses combined with sirolimus and induction antibody treatment...
  13. doi request reprint Frontiers in immunosuppression
    B D Kahan
    The University of Texas Medical School at Houston, Houston, TX, USA
    Transplant Proc 43:822-5. 2011
    ..Preliminary work in animal models supports these avenues for future drug development...
  14. ncbi request reprint Individuality: the barrier to optimal immunosuppression
    Barry D Kahan
    Division of Immunology and Organ Transplantation, Department of Surgery, University of Texas Medical School at Houston, Suite 6 240, 6431 Fannin, Houston, Texas 77030, USA
    Nat Rev Immunol 3:831-8. 2003
    ..Approaches presently under investigation aim to alter cell trafficking, or selectively deviate the maturation of antigen-presenting cells or inhibit lymphocyte-activation cascades - events that are crucial to rejection responses...
  15. ncbi request reprint RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection
    B D Kahan
    Division of Immunology and Organ Transplantation, The University of Texas Medical School at Houston, 6431 Fannin St, Suite 6 240, Houston, TX 77030, USA
    Transplantation 71:1400-6. 2001
    ....
  16. ncbi request reprint Sirolimus: a comprehensive review
    B D Kahan
    Division of Immunology and Organ Transplantation, University of Texas Houston, 6431 Fannin, Suite 6 240, Houston, TX 77030, USA
    Expert Opin Pharmacother 2:1903-17. 2001
    ....
  17. ncbi request reprint Therapeutic drug monitoring of immunosuppressant drugs in clinical practice
    Barry D Kahan
    Division of Immunology and Organ Transplantation, University of Texas Health Science Center at Houston Medical School, 77030, USA
    Clin Ther 24:330-50; discussion 329. 2002
    ..Therapeutic drug monitoring (TDM) is essential to maintain the efficacy of many immunosuppressant drugs while minimizing their toxicity. TDM has become more refined with the development of new monitoring techniques and more specific assays...
  18. ncbi request reprint Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus
    Barry D Kahan
    University of Texas Medical School at Houston, Department of Surgery, Division of Immunology and Organ Transplantation, Houston, Texas 77030, USA
    Ther Drug Monit 24:47-52. 2002
    ..These two new agents are likely to usher in a new era of transplant therapy...
  19. ncbi request reprint Current immunosuppressant regimens: considerations for critical care
    B D Kahan
    Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston, 6431 Fannin Street, Houston, TX 77030, USA
    Curr Opin Crit Care 7:242-50. 2001
    ..Among them, only FTY720 is undergoing large-scale human clinical trials. With its unique mechanism of action and synergistic interactions with cyclosporine and sirolimus, it may provide the foundation for a new era in immunosuppression...
  20. doi request reprint Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation
    Richard J Knight
    Department of Surgery, The Methodist Hospital, Houston, TX 77030, USA
    Transplantation 89:727-32. 2010
    ..A prednisone and calcineurin inhibitor (CNI)-free protocol was compared with a sirolimus, cyclosporine A (CsA), and prednisone-based immunosuppressive regimen for simultaneous pancreas-kidney transplantation (SPK)...
  21. doi request reprint Repeat renal allografts treated with sirolimus, cyclosporine, anti-thymocyte globulin induction and continuous steroids achieve similar immunosuppressive efficacy as primary transplants
    Virgilio G Petero
    Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston Medical School, Houston, TX 77030, USA
    Clin Transplant 24:243-51. 2010
    ..We sought to examine repeat versus primary renal transplantations using sirolimus-based regimens...
  22. ncbi request reprint Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients
    Robert M Langer
    The University of Texas Medical School at Houston, Department of Surgery, Division of Immunology and Organ Transplantation, Houston, TX 77030, USA
    Transplantation 74:804-8. 2002
    ..In a retrospective study we sought to dissect the factors associated with an increased occurrence of clinically significant perinephric fluid collections and lymphoceles among sirolimus-treated renal transplant recipients...
  23. ncbi request reprint Thymoglobulin, sirolimus, and reduced-dose cyclosporine provides excellent rejection prophylaxis for pancreas transplantation
    Richard J Knight
    Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston, Texas 77030, USA
    Transplantation 75:1301-6. 2003
    ....
  24. ncbi request reprint BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes
    Carlos A Benavides
    Division of Immunology and Organ Transplantation, Department of Surgery, University of Texas Medical School at Houston, Houston, TX, USA
    Transplantation 84:83-8. 2007
    ....
  25. ncbi request reprint Selectin inhibitor bimosiamose prolongs survival of kidney allografts by reduction in intragraft production of cytokines and chemokines
    Robert Langer
    Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School Houston, 6431 Fannin, Suite 6 240, Houston, TX 77030, USA
    J Am Soc Nephrol 15:2893-901. 2004
    ..Thus, BIMO blocks allograft rejection by reduction of intragraft expression of cytokines and chemokines...
  26. ncbi request reprint [Improved outcome with sirolimus-cyclosporine regimen in high-risk renal transplant recipients]
    Hemangshu Podder
    Division of Immunology and Organ Transplantation, The University of Texas Medical School at Houston, Houston, Texas 77030, USA
    Orv Hetil 146:1641-6. 2005
    ..Therefore, a good combination will allow not only to reduce individual immunosuppressive drug induced toxicities but will also allow to achieve better graft and patient survival...
  27. ncbi request reprint Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results
    George W Burke
    Department of Surgery, University of Miami, Miami, Florida 33136, USA
    Transplantation 77:1269-75. 2004
    ..Induction agents included T-cell-depleting and interleukin-2 receptor antibodies...
  28. doi request reprint Impact of reduced nephron mass on cyclosporine- and/or sirolimus-induced nephrotoxicity
    Ida Fernandes
    Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School, Houston, TX, USA
    Transplantation 88:1323-31. 2009
    ..We evaluated the impact of reduced nephron mass on nephrotoxicity by cyclosporine A (CsA) and/or sirolimus (SRL)...
  29. ncbi request reprint Allograft rejection requires STAT5a/b-regulated antiapoptotic activity in T cells but not B cells
    Ye Zhang
    Division of Immunology and Organ Transplantation, Department of Surgery, University of Texas Medical School, Houston, TX 77030, USA
    J Immunol 176:128-37. 2006
    ..Thus, activated STAT5a/b-/- T cells produce cytokines prior to entering apoptosis, thereby promoting differentiation of B cells yielding donor-specific IgM and IgG Ab that mediate allograft rejection...
  30. ncbi request reprint Selection of lowly immunogenic and highly tolerogenic donor and recipient allochimeric class I major histocompatibility complex proteins
    John Perez
    Department of Surgery, The University of Texas Medical School at Houston, Houston, Texas 77030, USA
    Transplantation 76:1201-7. 2003
    ..An rat alloantigen. We examined the potential of alpha1h-RT1. An versus alpha2h-RT1. An polymorphic AAs to induce accelerated rejection or tolerance of heart allografts...
  31. ncbi request reprint FTY720: A new kid on the block for transplant immunosuppression
    Fazil Tuncay Aki
    The University of Texas Medical School at Houston, Department of Surgery, Suite 6 240, 6431 Fannin, Houston, TX 77030, USA
    Expert Opin Biol Ther 3:665-81. 2003
    ..Clearly, structural analogues, as well as other agents that alter the balance of chemokines or affect cellular adhesion to activated endothelium, will represent important components of future regimens...
  32. ncbi request reprint Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis
    Shih Chieh J Chueh
    Division of Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston, Houston, TX, USA
    Transplantation 76:375-82. 2003
    ....
  33. ncbi request reprint Effect of sirolimus treatment on gene expression in renal transplant patients
    Kasey Vickers
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    World J Surg 31:644-53. 2007
    ..The rapamycin signaling pathway [mammalian target of rapamycin (mTOR)] has been implicated in transcriptional regulation...
  34. ncbi request reprint Interventional radiologic management of renal transplant dysfunction: indications, limitations, and technical considerations
    Katsuhiro Kobayashi
    Department of Diagnostic and Interventional Imaging, University of Texas Medical School at Houston, 6431 Fannin St, Houston, TX 77030, USA
    Radiographics 27:1109-30. 2007
    ..In addition, familiarity with the indications for and limitations of these techniques as well as collaboration between the radiologist and the transplantation surgeon are vital for maximizing the chances of renal allograft survival...
  35. ncbi request reprint Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients
    Richard J Knight
    Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston, Houston, TX, USA
    Clin Transplant 21:460-5. 2007
    ..As sirolimus has been implicated in impaired wound healing, the aim of this study was to evaluate risk factors for wound complications after renal transplantation in patients treated with this drug de novo...
  36. ncbi request reprint De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination
    Robert M Langer
    The University of Texas Medical School at Houston, Department of Surgery, Division of Immunology and Organ Transplantation, Suite 6 240, 6431 Fannin, Houston, TX 77030, USA
    Transplantation 73:756-60. 2002
    ..We sought to examine factors that predisposed 1.5% (10/672) of renal transplant recipients treated with a cyclosporine (CsA)/sirolimus (SRL)/steroid immunosuppressive regimen to develop hemolytic uremic syndrome (HUS)...
  37. ncbi request reprint Pancreas transplantation utilizing thymoglobulin, sirolimus, and cyclosporine
    Richard J Knight
    Division of Immunology and Organ Transplantation, The University of Texas Health Science Center, Houston, TX 77030, USA
    Transplantation 81:1101-5. 2006
    ..This study aims to determine the impact of thymoglobulin-sirolimus-cyclosporine immunosuppression on the alloimune response of pancreas-kidney transplant recipients...
  38. ncbi request reprint Losing the kingdom: the case against commercial organ donation
    Barry D Kahan
    Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas, Medical School, Houston, TX 77030, USA
    Nat Clin Pract Urol 4:290-1. 2007
  39. ncbi request reprint Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients
    Joel D Morrisett
    The Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    J Lipid Res 43:1170-80. 2002
    ....
  40. ncbi request reprint Allochimeric class I MHC protein-induced tolerance by partial TCR engagement requires activation of both CTL4- and common gamma-chain-dependent cytokine signals
    Stanislaw M Stepkowski
    Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston, Houston, Texas 77030, USA
    Transplantation 73:1227-35. 2002
    ..The various toxicities associated with the general immune suppression resulting from current clinical immunosuppressive therapies continue to plague transplant recipients as well as jeopardize allograft survival...
  41. ncbi request reprint The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function
    Richard J Knight
    Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Transplantation 78:904-10. 2004
    ..The present study reviews our experience with the substitution of thymoglobulin for basiliximab as induction therapy for recipients at increased risk for early acute rejection episodes...
  42. ncbi request reprint The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities
    Stanislaw M Stepkowski
    Division of Immunology and Organ Transplantation, Department of Surgery, University of Texas Medical School at Houston, Houston, TX 77030, USA
    J Immunol 175:4236-46. 2005
    ..In contrast to CsA, NC1153 was not metabolized by cytochrome P450 3A4. Thus, NC1153 prolongs allograft survival without several toxic effects associated with current immunosuppressive drugs...
  43. ncbi request reprint Long-term outcomes of single paediatric vs. ideal adult renal allograft transplants in adult recipients
    Zsolt Csapo
    Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Clin Transplant 20:423-6. 2006
    ..To compare the outcomes of single paediatric vs. adult kidneys transplanted into adult recipients...
  44. ncbi request reprint Sirolimus: a current perspective
    Yarkin K Yakupoglu
    The University of Texas Medical School at Houston, Department of Surgery, Division of Immunology and Organ Transplantation, 6431 Fannin, Suite 6 240, Houston, TX 77030, USA
    Exp Clin Transplant 1:8-18. 2003
    ..Therefore, sirolimus proffers a potent and unique platform for new immunosuppressive strategies in organ transplantation...
  45. ncbi request reprint Janus kinase 3: a novel target for selective transplant immunosupression
    Hemangshu Podder
    The University of Texas Medical School at Houston, Division of Immunology and Organ Transplantation, 6431 Fannin Street, Suite 6 240, Houston, TX 77030, USA
    Expert Opin Ther Targets 8:613-29. 2004
    ....
  46. ncbi request reprint 100 years ago: Ullmann's pioneering operation--autotransplantation of the kidney
    R M Langer
    Division of Immunology and Organ Transplantation, University of TexasMedical School at Houston, 6431 Fannin, Houston, TX 77030, USA
    Transplant Proc 34:429-33. 2002
  47. ncbi request reprint Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland 4002
    Am J Transplant 3:606-13. 2003
    ..Weight-adjusted dosing (mg/kg) does not appear warranted. Black patients may have lower bioavailability and/or higher clearance of everolimus compared with white patients...
  48. doi request reprint Accuracy and variability of equations to estimate glomerular filtration rates in renal transplant patients receiving sirolimus and/or calcineurin inhibitor immunosuppression
    James T Burke
    Wyeth Research, Paris, France
    Transpl Int 21:434-40. 2008
    ..001). The accuracy of the three eGFR equations was affected by mGFR range but not by immunosuppressive regimens utilizing SRL, SRL-CNI or CNI-based therapy...
  49. ncbi request reprint Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin
    Stanislaw M Stepkowski
    Department of Surgery Division of Immunology and Organ Transplantation and University of Texas Medical School at Houston, USA
    Blood 99:680-9. 2002
    ..It is concluded that inhibition of signal 3 alone by targeting Jak3 in combination with a signal 1 inhibitor provides a unique strategy to achieve potent immunosuppression...
  50. ncbi request reprint [Lymphocele and kidney transplantation]
    Robert Langer
    Semmelweis Egyetem, Általános Orvostudományi Kar, Transzplantációs és Sebészeti Klinika, Budapest
    Orv Hetil 148:1475-80. 2007
    ..Aim: From the point of view of the lymphocele a comparison was made for the risks and benefits of the conventional and a newer immunosuppressive combination...
  51. ncbi request reprint Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients
    Robert M Langer
    Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary
    Transplantation 76:318-23. 2003
    ....
  52. ncbi request reprint Toward calcineurin antagonist minimization
    Barry D Kahan
    Transplantation 77:162; author reply 162-3. 2004
  53. ncbi request reprint FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation
    Helio Tedesco-Silva
    Hospital do Rim e Hipertensao, Borges Lagoa 960, Sao Paulo, SP 04038 002, Brazil
    Transplantation 77:1826-33. 2004
    ..Its effect relates to the modulation of lymphocytes trafficking from blood and peripheral tissues to lymph nodes. This is the first study to evaluate the efficacy and safety of FTY720 in de novo renal transplantation...
  54. ncbi request reprint Metabolic interaction between cyclosporine and sirolimus
    Shuang Bai
    Pharmaceutics Division, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712 0126, USA
    Transplantation 77:1507-12. 2004
    ..Furthermore, both drugs affect the activity of cytochrome P450 3A1/2 (CYP3A1/2), the rat parallel to human CYP3A4, and the multidrug transporter P-glycoprotein (Pgp)...
  55. ncbi request reprint Clinical application of sirolimus in renal transplantation: an update
    Shih Chieh J Chueh
    Department of Urology, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan
    Transpl Int 18:261-77. 2005
    ....
  56. ncbi request reprint FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation
    Helio Tedesco-Silva
    Hospital do Rim e Hipertensao, Sao Paulo 04038 002, Brazil
    Transplantation 79:1553-60. 2005
    ..Its effect relates to the modulation of lymphocytes trafficking from blood and peripheral tissues to lymph nodes. This is the first study to evaluate the efficacy and safety of FTY720 in de novo renal transplantation...
  57. ncbi request reprint Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range
    John M Kovarik
    Novartis Pharmaceuticals, Basel, Switzerland
    Transplantation 73:920-5. 2002
    ..Exposure, safety, and efficacy data from the two everolimus randomized, double-blind phase 3 trials were evaluated to identify a therapeutic concentration range applicable in de novo kidney transplantation...
  58. ncbi request reprint Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies
    H Myron Kauffman
    Research Department, United Network for Organ Sharing, Richmond, VA, USA
    Transplantation 80:883-9. 2005
    ..In animal models, calcineurin inhibitors have a positive growth effect, whereas target-of-rapamycin (TOR) inhibitors have a negative growth effect on malignant cells...
  59. ncbi request reprint A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection
    Timothy H Mathew
    Clinical Pharmacology Department, A3042, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426, USA
    J Clin Pharmacol 46:76-87. 2006
    ..The tablet and solution formulations of sirolimus demonstrated therapeutic equivalence...
  60. ncbi request reprint Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation
    Helio Tedesco-Silva
    Setor de Transplante Renal, Hospital do Rim Hipertensão UNIFESP, Rua Borges, Lagoa, 960 11o andar, Sao Paulo, SP, Brazil
    Transplantation 82:1689-97. 2006
    ..Phase II trials of FTY720, a novel immunomodulator, have shown promise in preventing rejection with both standard and reduced cyclosporine exposure. This study was designed to confirm those findings...
  61. ncbi request reprint Review: metabolism of immunosuppressant drugs
    Patrick Kelly
    Novartis Pharmaceuticals Corp, Medical Affairs Transplantation, Summit, NJ 07901, USA
    Curr Drug Metab 3:275-87. 2002
    ..Because of the critical-dose nature of most of the recent generation of immunosuppressive agents, therapeutic drug monitoring is becoming increasingly important in the selection of doses and treatment regimens...
  62. ncbi request reprint Fokko Johannes van der Woude, 1953-2006
    Barry D Kahan
    Transplant Proc 39:321-4. 2007

Research Grants18

  1. PHARMACOLOGY OF CYCLOSPORINE BASED IMMUNOSUPPRESSION
    Barry Kahan; Fiscal Year: 2000
    ..In aggregate studies seek to describe quantitative the potential benefits and/or risks of CsA-based drug combinations in order to select agents suitable for use in clinical trials. ..
  2. PHARMACOLOGY OF CYCLOSPORINE-BASED IMMUNOSUPPRESSION
    Barry Kahan; Fiscal Year: 1993
    ....
  3. CYCLOSPORINE PHARMACOLOGY IN CLINICAL TRANSPLANTATION
    Barry Kahan; Fiscal Year: 1991
    ..The combined pharmacokinetic and pharmacodynamic approach will provide a foundation to design, monitor, evaluate and enhance with efficacy of CsA dosing regimens for renal, cardiac, hepatic and pancreatic transplant recipients...
  4. PHARMACOLOGY OF CYCLOSPORINE BASED IMMUNOSUPPRESSION
    Barry Kahan; Fiscal Year: 2004
    ....